Tardive Dyskinesia Impact Scale Captures Relevant Info About Condition
19 Jan 2024
Phase 3Clinical Result
FRIDAY, Jan. 19, 2024 -- The Tardive Dyskinesia Impact Scale (TDIS) patient-reported outcome measure captures information about the impact of TD, according to a study published online Jan. 4 in the Journal of Patient-Reported Outcomes.
Robert H. Farber, Ph.D., from Neurocrine Biosciences Inc. in San Diego, and colleagues used data from qualitative studies and phase 3 trials of a VMAT2 inhibitor for treatment of TD to determine the psychometric properties of the TDIS. To assess how well the TDIS captured key domains of TD impact, qualitative research included concept elicitation and cognitive debriefing interviews with TD patients and their caregivers. The psychometric properties of the TDIS were examined with quantitative analysis including assessing construct validity and responsiveness to change.
The researchers found that the key TD impacts reported by patients and caregivers were captured by the TDIS; the TDIS was interpreted as intended and relevant to patients' experiences based on qualitative results. Evidence of two underlying domains of the TDIS was found in quantitative results: physical and socioemotional. Compared with the clinician-rated outcome (Abnormal Involuntary Movement Scale), the TDIS captured unique content based on known groups and predictive validity. Responsiveness to change in treatment was seen with the TDIS, with improvement noted in TDIS scores over 48 weeks in two phase 3 trials.
"The TDIS can be easily administered in a clinician's office or at a patient's home to provide insight about TD impact and whether the impact is lessening or increasing," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Neurocrine Biosciences, which funded the study.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.